Oseltamivir

Influenza is a respiratory infectious disease with high seasonal incidence globally, which can cause 3 to 5 million severe cases every year. Neuraminidase inhibitors are the core medications for current anti-influenza virus treatment. Oseltamivir is a selective neuraminidase inhibitor. By inhibiting the activity of neuraminidase on the surface of influenza viruses, it blocks the release and spread of viruses from infected host cells. It is one of the few oral antiviral drugs currently effective against both influenza A and influenza B. It can be used for influenza treatment in people aged 1 year and above, as well as post-exposure prophylaxis against influenza in people aged 13 years and above, and is the preferred drug for early diagnosis and early treatment of influenza recommended by clinical guidelines.

In 2023, the market size of domestic oseltamivir API exceeded 1.8 billion yuan. Driven by factors such as the periodic epidemic of influenza and the increasing demand for pediatric medications, the compound growth rate in the past three years has reached 27%. In terms of the competitive landscape, after the patent of the original research manufacturer Roche expired, more than 20 domestic enterprises have obtained the production qualification for oseltamivir API, with production capacity mainly concentrated in Guangdong, Zhejiang and other regions. After the implementation of volume-based procurement, the proportion of API cost in the total cost of preparations has increased from 35% to 52%, and the demand of downstream preparation enterprises for high-purity, compliant APIs and supporting impurity reference substances continues to rise.

As a professional supplier deeply engaged in the field of API impurity research, CATO can provide a full set of impurity reference standards for oseltamivir API. All products support compliance certification under multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, with complete structural confirmation and purity calibration data. Core specifications are kept in stock, which can quickly respond to the needs of the whole process scenarios such as API R&D, quality research, registration and declaration, helping enterprises shorten project cycles and reduce compliance risks.